Veracyte Inc (VCYT) 13.30 $VCYT
Nasdaq stocks posting largest percentage decreases
AP - Mon Apr 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Veracyte (VCYT) Jumps: Stock Rises 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:21AM CDT
Veracyte, Inc. (VCYT) was a big mover last session, as the company saw its shares rise by over 8% on the day.
Why First Solar, Veracyte, and KB Home Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Mar 19, 7:00PM CDT
Most investors believed that the Federal Open Market Committee's meeting today would prove to be a non-event. But while the continuation of the Fed taper didn't surprise anyone, Fed Chair Janet Yellen's comments during the subsequent press conference...
Veracyte, Inc. Announces Fourth Quarter and Full-Year 2013 Financial Results, Provides 2014 Financial Outlook
PR Newswire - Tue Mar 18, 3:05PM CDT
Veracyte, Inc. (Nasdaq: VCYT) today reported financial results and business progress for the quarter and full year ended December 31, 2013, and provided financial guidance for 2014. Revenue was $6.8 million for the fourth quarter of 2013, an increase of 53%, compared to 2012 fourth quarter revenue of $4.5 million. Full-year 2013 revenue was $21.9 million, an increase of 88%, compared to full-year 2012 revenue of $11.6 million.
Veracyte, Inc. Appoints Julie A. Brooks as Executive Vice President, General Counsel and Secretary; and Andy Thorson as Executive Vice President, Corporate Strategy and Business Development
PR Newswire - Mon Mar 17, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointments of two executives to its management team. Julie A. Brooks joins the company as executive vice president, general counsel and secretary; and Andy Thorson joins as executive vice president, corporate strategy and business development.
Veracyte, Inc. to Announce Fourth Quarter and Full-Year 2013 Financial Results and Host Conference Call on Tuesday, March 18, 2014
PR Newswire - Tue Mar 11, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its fourth quarter and full-year 2013 financial results after close of market on Tuesday, March 18, 2014. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and business progress.
Can Veracyte (VCYT) Continue to Rise? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:02AM CST
Can Veracyte (VCYT) Continue to Rise?
Veracyte Updates Presentation Date and Time at the Cowen and Company 34th Annual Health Care Conference
PR Newswire - Mon Mar 03, 12:27PM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced a change in the company's presentation date and time at the Cowen and Company 34th Annual Health Care Conference. Bonnie H. Anderson, president and chief executive officer, will present on Tuesday, March 4, 2014 at 8:00 a.m. ET in the St. Botolph room at The Boston Marriott Copley Place in Boston, Mass.
Veracyte to Present at Cowen and Company 34th Annual Health Care Conference
PR Newswire - Wed Feb 26, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Cowen and Company 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 10 a.m. ET in Boston, Mass.
Veracyte To Present At 2014 Leerink Global Healthcare Conference
PR Newswire - Wed Feb 05, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 11:30 a.m. ET in New York.
Veracyte Announces Cigna Coverage for the Afirma® Gene Expression Classifier
PR Newswire - Mon Dec 16, 3:30PM CST
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that Cigna, one of the nation's leading providers of health insurance, has issued a positive coverage policy for the company's Afirma Gene Expression Classifier (GEC). The new policy applies to approximately 13 million of Cigna's medical customers and is effective immediately. The Afirma GEC is used to help patients avoid unnecessary surgery as part of thyroid cancer diagnosis and to reduce healthcare costs. Cigna joins Aetna, Humana, Medicare, UnitedHealthcare and other commercial payers in covering Afirma, collectively representing over 115 million covered lives.
Why Veracyte Inc. Shares Stormed Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Nov 26, 12:32PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Veracyte , a recently IPO'd molecular...
Veracyte Inc posts higher net loss of USD6.3m in Q3 2013
M2 - Tue Nov 26, 6:28AM CST
Diagnostics company Veracyte Inc (NasdaqGM:VCYT) on Monday declared a net loss of USD6.3m (USD6.59 per common share) for the third quarter ended 30 September 2013.
Veracyte, Inc. Announces Third Quarter 2013 Financial Results
PR Newswire - Mon Nov 25, 3:05PM CST
Veracyte, Inc. (Nasdaq: VCYT) today reported financial results for the third quarter ended September 30, 2013, and provided an update on recent business progress. Revenue was $5.6 million for the third quarter of 2013, versus $3.2 million for the third quarter of 2012, an increase of 74%. Revenue for the first nine months of 2013 was $15.0 million, compared to $7.2 million for the first nine months of 2012, an increase of 110%.
Veracyte Presents Data Suggesting Ability of Its Afirma® Gene Expression Classifier To Detect Medullary Thyroid Cancer Among Indeterminate Thyroid Nodule Biopsies
PR Newswire - Wed Nov 13, 7:15AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that it presented new data suggesting the ability of its Afirma Gene Expression Classifier (GEC) to accurately identify medullary thyroid cancer (MTC) among thyroid nodule fine needle aspiration (FNA) samples that are indeterminate and sub-classified as Hurthle cell neoplasms by cytopathology. The findings were presented in a poster session at the American Society of Cytopathology's 61st Annual Scientific Meeting held November 8-12 in Orlando, Fla.
Veracyte, Inc. to Announce Third Quarter 2013 Financial Results and Host Conference Call on Monday, November 25, 2013
PR Newswire - Mon Nov 11, 7:15AM CST
Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2013 financial results will be released after close of market on Monday, November 25, 2013. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
Nasdaq stocks posting largest percentage decreases
AP - Mon Apr 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Veracyte (VCYT) Jumps: Stock Rises 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:21AM CDT
Veracyte, Inc. (VCYT) was a big mover last session, as the company saw its shares rise by over 8% on the day.
Why First Solar, Veracyte, and KB Home Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Mar 19, 7:00PM CDT
Most investors believed that the Federal Open Market Committee's meeting today would prove to be a non-event. But while the continuation of the Fed taper didn't surprise anyone, Fed Chair Janet Yellen's comments during the subsequent press conference...
Veracyte, Inc. Announces Fourth Quarter and Full-Year 2013 Financial Results, Provides 2014 Financial Outlook
PR Newswire - Tue Mar 18, 3:05PM CDT
Veracyte, Inc. (Nasdaq: VCYT) today reported financial results and business progress for the quarter and full year ended December 31, 2013, and provided financial guidance for 2014. Revenue was $6.8 million for the fourth quarter of 2013, an increase of 53%, compared to 2012 fourth quarter revenue of $4.5 million. Full-year 2013 revenue was $21.9 million, an increase of 88%, compared to full-year 2012 revenue of $11.6 million.
Veracyte, Inc. Appoints Julie A. Brooks as Executive Vice President, General Counsel and Secretary; and Andy Thorson as Executive Vice President, Corporate Strategy and Business Development
PR Newswire - Mon Mar 17, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointments of two executives to its management team. Julie A. Brooks joins the company as executive vice president, general counsel and secretary; and Andy Thorson joins as executive vice president, corporate strategy and business development.
Veracyte, Inc. to Announce Fourth Quarter and Full-Year 2013 Financial Results and Host Conference Call on Tuesday, March 18, 2014
PR Newswire - Tue Mar 11, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its fourth quarter and full-year 2013 financial results after close of market on Tuesday, March 18, 2014. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and business progress.
Can Veracyte (VCYT) Continue to Rise? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:02AM CST
Can Veracyte (VCYT) Continue to Rise?
Veracyte Updates Presentation Date and Time at the Cowen and Company 34th Annual Health Care Conference
PR Newswire - Mon Mar 03, 12:27PM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced a change in the company's presentation date and time at the Cowen and Company 34th Annual Health Care Conference. Bonnie H. Anderson, president and chief executive officer, will present on Tuesday, March 4, 2014 at 8:00 a.m. ET in the St. Botolph room at The Boston Marriott Copley Place in Boston, Mass.
Veracyte to Present at Cowen and Company 34th Annual Health Care Conference
PR Newswire - Wed Feb 26, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Cowen and Company 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 10 a.m. ET in Boston, Mass.
Veracyte To Present At 2014 Leerink Global Healthcare Conference
PR Newswire - Wed Feb 05, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 11:30 a.m. ET in New York.
Veracyte Announces Cigna Coverage for the Afirma® Gene Expression Classifier
PR Newswire - Mon Dec 16, 3:30PM CST
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that Cigna, one of the nation's leading providers of health insurance, has issued a positive coverage policy for the company's Afirma Gene Expression Classifier (GEC). The new policy applies to approximately 13 million of Cigna's medical customers and is effective immediately. The Afirma GEC is used to help patients avoid unnecessary surgery as part of thyroid cancer diagnosis and to reduce healthcare costs. Cigna joins Aetna, Humana, Medicare, UnitedHealthcare and other commercial payers in covering Afirma, collectively representing over 115 million covered lives.
Why Veracyte Inc. Shares Stormed Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Nov 26, 12:32PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Veracyte , a recently IPO'd molecular...
Veracyte Inc posts higher net loss of USD6.3m in Q3 2013
M2 - Tue Nov 26, 6:28AM CST
Diagnostics company Veracyte Inc (NasdaqGM:VCYT) on Monday declared a net loss of USD6.3m (USD6.59 per common share) for the third quarter ended 30 September 2013.
Veracyte, Inc. Announces Third Quarter 2013 Financial Results
PR Newswire - Mon Nov 25, 3:05PM CST
Veracyte, Inc. (Nasdaq: VCYT) today reported financial results for the third quarter ended September 30, 2013, and provided an update on recent business progress. Revenue was $5.6 million for the third quarter of 2013, versus $3.2 million for the third quarter of 2012, an increase of 74%. Revenue for the first nine months of 2013 was $15.0 million, compared to $7.2 million for the first nine months of 2012, an increase of 110%.
Veracyte Presents Data Suggesting Ability of Its Afirma® Gene Expression Classifier To Detect Medullary Thyroid Cancer Among Indeterminate Thyroid Nodule Biopsies
PR Newswire - Wed Nov 13, 7:15AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that it presented new data suggesting the ability of its Afirma Gene Expression Classifier (GEC) to accurately identify medullary thyroid cancer (MTC) among thyroid nodule fine needle aspiration (FNA) samples that are indeterminate and sub-classified as Hurthle cell neoplasms by cytopathology. The findings were presented in a poster session at the American Society of Cytopathology's 61st Annual Scientific Meeting held November 8-12 in Orlando, Fla.
Veracyte, Inc. to Announce Third Quarter 2013 Financial Results and Host Conference Call on Monday, November 25, 2013
PR Newswire - Mon Nov 11, 7:15AM CST
Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2013 financial results will be released after close of market on Monday, November 25, 2013. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
